British biotech execs sour on industry’s 'dire' shape

Investors have sourced on publicly traded biotech companies in a big way. IPOs appear to be a less and less appealing way to cash out venture players. And don't look for any kind of a change near-term.

That bleak message has just been repeated for readers of the Financial Times, who were treated to a series of negative assessments from some of the U.K.'s top biotech execs. Too many trial disappointments in too short a period of time has been fingered for much of the blame. 

One sample of the industry's view: "While there are some very strong companies developing--including Oxford BioMedica [1], Acambis [2] and Protherics--the sector is really in dire shape," says Glyn Edwards, chief executive of Antisoma.

- read the article [3] in the Financial Times

Related Articles:
Investor says biotech is languishing in the U.K. [4]
Bleak market will slam European research efforts [5]
European investors sour on biotech market [6]
Biopharma execs sign on to tout UK's R&D work [7]